This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Caris Life Sciences, Inc. (CAI)

Tipranks - Tipranks - Fri May 15, 3:24AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Crispr Therapeutics AG (CRSP) and Caris Life Sciences, Inc. (CAI) with bullish sentiments.

Claim 55% Off TipRanks

Crispr Therapeutics AG (CRSP)

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Crispr Therapeutics AG, with a price target of $83.00. The company’s shares closed last Wednesday at $52.75.

According to TipRanks.com, Stranahan is a 5-star analyst with an average return of 10.3% and a 52.8% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, Perspective Therapeutics, and Janux Therapeutics Inc. ;'>

Currently, the analyst consensus on Crispr Therapeutics AG is a Moderate Buy with an average price target of $71.77, implying a 35.9% upside from current levels. In a report issued on May 5, William Blair also maintained a Buy rating on the stock.

See the top stocks recommended by analysts >>

Caris Life Sciences, Inc. (CAI)

In a report released yesterday, Michael Ryskin from Bank of America Securities maintained a Buy rating on Caris Life Sciences, Inc., with a price target of $28.00. The company’s shares closed last Wednesday at $14.69, close to its 52-week low of $14.19.

According to TipRanks.com, Ryskin is a 2-star analyst with an average return of 0.1% and a 47.7% success rate. Ryskin covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Tempus AI, Inc. Class A, and Fortrea Holdings Inc. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Caris Life Sciences, Inc. with a $27.92 average price target, representing a 73.9% upside. In a report issued on May 8, TD Cowen also maintained a Buy rating on the stock with a $31.00 price target.

Read More on CRSP:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).